Sivertsson R, Andersson O, Hansson L
Acta Med Scand. 1979;205(6):477-82.
Systemic BP reduction, calf blood flow and vascular resistance in the calf were determined in forty-two previously untreated patients with mild to moderate essential hypertension (WHO I-WHO II) before and after 6 weeks, 6 months and 18 months of BP-lowering treatment with mefruside (25 mg daily) or atenolol (100--400 mg daily). Blood flow was determined with venous occlusion plethysmography using a mercury-in-rubber strain gauge technique in the supine patient. Auscultatory BP was measured on the right arm simultaneously with the flow determinations and resistance was calculated from the flow and pressure. BP was reduced significantly and to the same extent by the two drugs. In the atenolol group a rise in resting resistance and a corresponding fall in resting blood flow was seen initially. These changes were entirely normalized during continued treatment for 18 months. In the mefruside group no significant haemodynamic changes during treatment were observed at rest apart from the BP fall. None of the drugs reduced resistance at "maximal" vasodilatation, indicating that no regress of the hypertensive structural changes of the calf blood vessels had taken place.
对42例未经治疗的轻至中度原发性高血压患者(WHO I级 - WHO II级),在使用美夫西特(每日25毫克)或阿替洛尔(每日100 - 400毫克)进行降压治疗前、治疗6周、6个月及18个月后,测定其全身血压降低情况、小腿血流量及小腿血管阻力。采用汞柱式应变片技术,通过静脉阻塞体积描记法,在仰卧位患者身上测定血流量。在测定血流量的同时,于右臂测量听诊血压,并根据血流量和压力计算阻力。两种药物均使血压显著降低且降低程度相同。在阿替洛尔组,最初可见静息阻力升高及相应的静息血流量下降。在持续治疗18个月期间,这些变化完全恢复正常。在美夫西特组,除血压下降外,治疗期间静息时未观察到明显的血液动力学变化。两种药物在“最大”血管扩张时均未降低阻力,表明小腿血管高血压性结构改变未出现消退。